216 related articles for article (PubMed ID: 31980330)
1. Impact of HCV eradication with direct-acting antiviral agents on serum gamma globulin levels in HCV and HCV/HIV coinfected patients.
Milazzo L; van den Bogaart L; Sollima S; Oreni L; Lai A; Morena V; Bonazzetti C; Ridolfo Anna L; Antinori S
Eur J Intern Med; 2020 May; 75():50-54. PubMed ID: 31980330
[TBL] [Abstract][Full Text] [Related]
2. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
[TBL] [Abstract][Full Text] [Related]
3. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
4. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
[TBL] [Abstract][Full Text] [Related]
5. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
7. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response.
Corma-Gómez A; Macías J; Morano L; Rivero A; Téllez F; Ríos MJ; Santos M; Serrano M; Palacios R; Merino D; Real LM; De Los Santos I; Vera-Méndez FJ; Galindo MJ; Pineda JA;
Clin Infect Dis; 2021 Mar; 72(5):e96-e102. PubMed ID: 33211801
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
9. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
[TBL] [Abstract][Full Text] [Related]
10. HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests.
Domínguez Domínguez L; Matarranz M; Lagarde M; Bisbal O; Hernando A; Lumbreras C; Rubio R; Pulido F
Rev Esp Enferm Dig; 2019 Aug; 111(8):626-632. PubMed ID: 31240941
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
12. Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects.
Bono V; Tincati C; Van Den Bogaart L; Cannizzo ES; Rovito R; Augello M; De Bona A; D'Arminio Monforte A; Milazzo L; Marchetti G
Viruses; 2022 Jul; 14(8):. PubMed ID: 35893661
[TBL] [Abstract][Full Text] [Related]
13. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
[TBL] [Abstract][Full Text] [Related]
15. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
16. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
17. [Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients].
Liao BL; Li LH; Zhong HL; Li H; Li YH; Chen SZ; Wen CY; Hu FY; Lan Y; Cai WP
Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):776-780. PubMed ID: 34517460
[No Abstract] [Full Text] [Related]
18. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
Macías J; Granados R; Téllez F; Merino D; Pérez M; Morano LE; Palacios R; Paniagua M; Frías M; Merchante N; Pineda JA;
J Viral Hepat; 2019 Jan; 26(1):16-24. PubMed ID: 30141222
[TBL] [Abstract][Full Text] [Related]
19. HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy.
Álvarez B; Navarrete-Muñoz MA; Briz V; Olmedillas-López S; Nistal S; Cabello A; Prieto L; Górgolas M; García-Arranz M; Benito JM; Rallón N
Sci Rep; 2022 Mar; 12(1):5095. PubMed ID: 35332180
[TBL] [Abstract][Full Text] [Related]
20. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
